Over-Expression of 60s Ribosomal L23a Is Associated with Cellular Proliferation in SAG Resistant Clinical Isolates of Leishmania donovani

PLoS Neglected Tropical Diseases

Volumn 7, Issue 12, 2013, Pages

  Das, Sanchita ^a   Shah, Priyanka ^a   Baharia, Rajendra K ^a   Tandon, Rati ^a   Khare, Prashant ^a   Sundar, Shyam ^b   Sahasrabuddhe, Amogh A ^a   Siddiqi, M I ^a   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC G 418; ANTIMONY GLUCONATE; MILTEFOSINE; PAROMOMYCIN; POLYCLONAL ANTIBODY; RIBOSOME PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH CURVE; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOLOCALIZATION; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SPLEEN BIOPSY; WESTERN BLOTTING;

ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; CYTOSOL; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEISHMANIA DONOVANI; MESOCRICETUS; MICE; REAL-TIME POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS;

EID: 84892749406     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002527     Document Type: Article

References (43)

1. Croft SL, Coombs GH, (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends parasitology 19: 502-508.
2. Sundar S, Murray HW, (2005) Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 83: 394-395.
3. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in Leishmaniasis. Clin Microbiol Rev 19: 111-126.
4. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, et al. (2011) Characterization of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol 41: 1311-21.
5. Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, et al. (2013) Antimony resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1,. Proc Natl Acad Sci USA 12: 110.E575-E585.
6. Biyani N, Singh AK, Mandal S, Chawla B, Madhubala R, (2011) Differential expression of protein in antimony-susceptible and-resistant isolates of Leishmania donovani. Mol Biochem Parasitol 179: 91-9.
7. Decuypere S, Rijal S, Yardley V, Doncker SD, Laurent T, et al. (2005) Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrobial Agents and Chemotherapy 49: 4616-4621.
8. Chawla B, Jhingran A, Panigrahi A, Stuart KD, Madhubala R, (2011) Paramomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paramomycin-susceptible-resistant Leishmania donovani. PLoS One 6: e26660.
9. Asutosh, Sundar S, Goyal N, (2007) Molecular mechanism of antimony resistance in Leishmania. J Med Microbiol 56: 143-53.
10. Kumar A, Sisodia B, Misra P, Shasany AK, Sundar S, et al. (2010) Proteomic mapping of over-expressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol 70: 609-617.
11. Naora H, Naora H, (1999) Involvement of ribosomal proteins in regulating cell growth and apoptosis: Translation modulation or recruitment for extraribosomal activity? Immunology and Cell Biology 77: 197-205.
12. Wool IG, (1996) Extraribosomal functions of ribosomal proteins. Trends Biochem Sci 21: 164-5.
13. Bavsar RV, Makley LN, Tsonis PA, (2010) The other lives of ribosomal proteins. Human Genomics 4: 327-44.
14. Lakshmi V, Pandey K, Kapil A, Singh N, Samant M, et al. (2007) In vitro and in vivo leishmanicidal activity of Dysoxylum binectariferum and its fractions against Leishmania donovani. Phytomedicine 14: 36-42.
15. Samant M, Gupta R, Kumari S, Misra P, Khare P, et al. (2009) Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-Type immunoprotective response against experimental visceral leishmaniasis. J Immunol 183: 470-9.
16. Mittal MK, Rai S, Ashutosh, Ravinder, Gupta S, et al. (2007) Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg 76: 681-8.
17. Guru PY, Agarwal AK, Singha UK, Singhal A, Gupta CM, (1989) Drug targeting in Leishmania donovani infections using infections using tuftsin bearing liposomes as drug vehicles. FEBS Lett 245: 204-8.
18. Dube A, Singh N, Sundar S, Singh N, (2005) Refractories to treatment of sodium stibogluconate in Indian kala-azar field isolates persists in in vitro and in vivo experimental models. Parasitol Res 96: 216-23.
19. Kushwaha PK, Gupta R, Tripathi CDP, Sundar S, Dube A, (2012) Evaluation of Leishmania donovani protein disulphide isomerase as a potential immunogeneic protein/vaccine candidate against visceral Leishmaniasis. PLoS One 7: 1-14.
20. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
21. Towbin H, Staehelin T, Gordon J, (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4.
22. Söding J, Biegert A, Lupas AN, (2005) The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acid Res 33: 244-8.
23. Sali A, Blundell TL, (1993) Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
24. Rama IS, Dea-Ayuela MA, Sanchez-Brunete JA, Torrado JJ, Alunda JM, et al. (2006) Real time reverse transcription PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation. Antimicrob Agents Chemother 50: 1195-1201.
25. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real time quantitave PCR and 2-Δ ΔCT method. Methods 25: 402-408.
26. Ashutosh, Garg M, Sundar S, Duncan R, Nakhasi HL, et al. (2011) Downregulation of mitogen-activated protein kinase I of Leishmania donovani field isolates is associated with antimony resistance. Antimicrobial agent and chemotherapy 56: 518-525.
27. Ha DS, Schwarz JK, Turco SJ, Beverley SM, (1996) Use of the green fluorescent protein as a marker in transfected Leishmania. Mol Biochem Parasitol 77: 57-64.
28. Dutta A, Bandopadhyay S, Mandal C, Chatterjee M, (2007) Aloe vera leaf exudates induces a caspase-independent cell death in Leishmania donovani promastigotes. J Med Microbiol 56 (5) (): 629-36.
29. Singh N, Kumar A, Gupta P, Chand K, Samant M, et al. (2008) Evaluation of antileishmanial potential of tinospora sinensis against experimental visceral leishmaniasis. Parasitol Res 102: 561-5.
30. Finney DJ. (1971) Probit analysis. 3rd ed. Cambridge, United Kingdom: Cambridge University Press.
31. Sahasrabuddhe AA, Bajpai VK, Gupta CM, (2004) A novel form of actin in Leishmania: molecular characterisation, subcellular localisation and association with subpellicular microtubules. Mol Biochem Parasitol 134: 105-114.
32. Kim JH, You KR, Kim IH, Cho BH, Kim CY, et al. (2004) Over-expression of the ribosomal protein L36a gene is associated with cellular proliferation in hepatocellular carcinoma. Hepatology 39: 129-38.
33. Jiang H, Lin JJ, Tao J, Fisher PB, (1997) Supression of human ribosomal protein L23a expression during cell growth inhibition by interferon-beta. Oncogene 14: 473-80.
34. Moorthamer M, Chaudhuri B, (1999) Identification of ribosomal protein L34 as a novel Cdk5 inhibitor. Biochem Biophys Res Commun 255: 631-8.
35. Takagi M, Absalon MJ, McLure KG, Kastan MB, (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123: 49-63.
36. Bruchhaus I, Roeder T, Rennenberg A, Heussler VT, (2007) Protozoan parasites: programmed cell death as a mechanism of parasitism,. Trends parasitol 23: 376-383.
37. Smirlis D, Duszenko M, Ruiz AJ, Scoulica E, Bastien P, et al. (2010) Targeting essential pathways in trypanosomatids gives insight into protozoan mechanisms of cell death. Parasites and Vectors 3: 1-15.
38. Debrabant A, Lee N, Bertholet S, Duncan R, Nakhasi HL, (2003) Programmed cell death in trypanpsomatids and unicellular organisms,. Int J Parasitol 33: 257-267.
39. Haldar AK, Sen P, Roy S, (2011) Use of antimony in treatment of Leishmaniasis: current status and future directions. Molecular Biology International 2011: 1-23.
40. Pérez-Victoria FJ, Cañete MPS, Seifert K, Croft SL, Sundar S, et al. (2006) Mechanism of experimental resistance of Leishmania to miltefosine: Implication for clinical use. Drug Resistance update 9: 26-39.
41. Hernández RG, Manzanos IJ, Castanys S, Gammaro F, (2012) Leishmania donovani is able to induce drug resistance to drug combinations. PLoS Negl Trop Dis 6: 1-9.
42. Lipstith M, Levin BR, (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41: 363-73.
43. Lipstith M, Levin BR, (1997) The within-host population dynamics of antibacterial chemotherapy conditions for the evolution of resistance. Ciba found. Symp 207: 112-130.